Navigation Links
Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
Date:9/25/2007

CHAMPAIGN, Ill. By better understanding how antimicrobials bind and thereby get inactivated in the mucus of air passages, researchers at the University of Illinois may have found a way to help cystic fibrosis patients fight off deadly infections.

While not a cure, this work has potential as a therapeutic strategy against bacterial infections in cystic fibrosis, said Gerard Wong a professor of materials science and engineering, of physics, and of bioengineering at the U. of I., and a corresponding author of a paper accepted for publication in the Proceedings of the National Academy of Sciences. The paper is to be posted this week on the journals Web site.

Ordinarily, pulmonary passages are lined with a thin layer of mucus that traps bacteria and other pathogens. Moved along by the motions of countless cilia, the mucus also acts as a conveyor belt that disposes of the debris. In patients with cystic fibrosis, however, the mucus is more like molasses thick and viscous. Because the cilia can no longer move the mucus, the layer becomes stuck, and the bacteria grow, multiply and colonize. Long-term bacterial infections are the primary cause of death in cystic fibrosis.

Using synchrotron X-ray scattering and molecular dynamics simulations, the researchers took a closer look at the mucous mess.

Debris in the infected mucus includes negatively charged, long-chained molecules such as mucin, DNA and actin (from dead white blood cells). It turns out most of the bodys antimicrobials, such as lysozyme, are positively charged.

We found that actin and lysozyme two of the most common components in infected mucus form ordered bundles of aligned molecules, which is something you dont expect in something as messy as mucus, said Wong, who also is a researcher at the universitys Beckman Institute. Held together tightly by the attraction of opposite charge, these bundles basically lock up the antimicrobials so that they are unable to kill bacteria.

The re
'/>"/>

Contact: James E. Kloeppel
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists discover basic defect in cystic fibrosis airway glands
2. Study reveals how cells destroy faulty proteins in cystic fibrosis
3. Discovery could aid fight against cystic fibrosis infection
4. Clues to gene expression in cystic fibrosis will guide research
5. Key found to kill cystic fibrosis superbug
6. Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment
7. Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients
8. Extra-aggressive form of idiopathic pulmonary fibrosis identified
9. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
10. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
11. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...t Norman has received more than $10 million in res... the federal stimulus program, bringing thetotal a...rs to $23 million. Thirty-three projects achieved...logy to weather. , "The university has thoughtfu...reasof scholarly excellence to federal agency prio...
(Date:11/4/2009)...PRNewswire-FirstCall/ -- Quest Diagnostics Incorpo...of diagnostic testing, information and services, a...r 30, 2009, income from continuing operations rose... $160 million, or $0.81 per diluted share, for the...ults were reduced by a $0.03 per share charge asso...
(Date:11/4/2009)... Aware, Inc. (Nasdaq: AW...nd biometrics software, today reported financial r...2009. ,, Michael Tzannes, Aware,s Chairman an...e announced an agreement to sell our DSL and home ...semiconductor company being spun out of Infineon. ...
Breaking Biology News(10 mins):OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 1EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 2NeurogesX Reports Second Quarter 2009 Results 13446 1NeurogesX Reports Second Quarter 2009 Results 13446 2NeurogesX Reports Second Quarter 2009 Results 13446 3NeurogesX Reports Second Quarter 2009 Results 13446 4NeurogesX Reports Second Quarter 2009 Results 13446 5NeurogesX Reports Second Quarter 2009 Results 13446 6NeurogesX Reports Second Quarter 2009 Results 13446 7NeurogesX Reports Second Quarter 2009 Results 13446 8NeurogesX Reports Second Quarter 2009 Results 13446 9NeurogesX Reports Second Quarter 2009 Results 13446 10NeurogesX Reports Second Quarter 2009 Results 13446 11NeurogesX Reports Second Quarter 2009 Results 13446 12
...rrow Neurological Institute at St. Joseph,s Hospit...k between eye motions and the perception of illuso...Stephen Macknik, PhD, director of the Laboratory o...e, PhD, director of the Laboratory of Visual Neuro...illan; conducted a study based on the Enigma paint...
... have grown soybeans and turned them into many use...hy a soybean grows, blooms or produces like it doe... , University of Georgia professor Wayne Parrott...million grant from the National Science Foundation...ue. , "I,m convinced that soybeans would be so mu...
... city dwellers posed by Southern California wildfi...restimated by officials. , Detailed particulate a...ia wild fires indicates that the composition posed...generally realized, according to a new paper analy...thern California. , The paper, entitled "Physico...
Other Biology News:Soybean grant gives researchers tools to unravel better bean 2Where there's wildfire smoke, there's toxicity 2
(Date:11/9/2009).... 9 NexBio, Inc. announced the pre...College of Allergy, Asthma, and Immunology in Miam... (Fludase®), a Sialidase, Decreases Airway Re...in Animal Models of Asthma". ,, DAS181 (Fludase...t-targeting drug candidate being studied in human ...
(Date:11/9/2009)...vember 9 Following the provision o...Drug Administration (FDA), privately,owned UK comp...international.com ) has been informed that its inn...n awarded an Orphan-Drug,designation for the treat..., ALS, also known as Lou Gehrig,s disease, is ...
(Date:11/6/2009)...6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc...iled the Form 52-109F1 Certification of Annual Fil...r and James Long, the Chief Financial Officer (the...in connection with the annual audited financial st..., The Company initially filed the annual financi...
(Date:11/6/2009)...stria, November 6 EUCODIS Bioscien...ng, and marketing enzymes for the,chemical industr...rch,agreement with Bio Sidus, the leading biopharm... agreement gives EUCODIS Bioscience exclusive acce...o Sidus, proprietary collection of,psychrophilic b...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2
...ed for the First Time on 50 mg/Day Dose for PRISTI...ssive Disorder, COLLEGEVILLE, Pa., Dec. 12 Wyeth...), announces that data from,two Phase 3 clinical s...gational serotonin-norepinephrine reuptake inhibit... a 50 mg/day dose of PRISTIQ for the,treatment of ...
...he Netherlands, December 12 , - Forty-five Presti...Response to Customer Demand, Elsevier, a leading ...M) information, today announced that 45 French-lan...e available on ScienceDirect beginning January,3, ...gie, Journal de Chirurgie and,La Press Medicale, r...
...IND has Been Filed With the FDA for the Fourth Gen...Collaboration with Roche., COPENHAGEN, December 1...nvestigational New Drug application (IND) for a,Ge...oration with Roche has,been filed with the FDA by ...velopment of the antibody which selectively blocks...
Other Biology Technology:New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6ScienceDirect to Host French-Language Journals from Elsevier Masson 2ScienceDirect to Host French-Language Journals from Elsevier Masson 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Nutrient Mixture F-12 Ham, Coon's Modification (Ham's F-12 Coon's) from Sigma-Aldrich
...solution is an isotonic, balanced salt solution. I...ervative, which permits the storage of whole blood... weeks.1 For usage, an equal volume of blood is co...y, but thoroughly, mixed. The solution is placed i...
...Mix or individual RNA sequences from high throughp...om small RNAs from LC Sciences. These products pro...ons) of DESIGNED sequences delivered in a microtub...taining a single verified RNA sequence. This is a ...
Biology Products: